TEVA PHARMACEUTICAL INDUSTRIES LTD
For the period ended Dec 31, 2025. Filed Feb 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 3, 2026
TEVA$42.97+0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Schedule II—Valuation and Qualifying Accounts
Three Years Ended December 31, 2025
(U.S. $ in millions)
| Column A · Column B · Column C · Column D · Column E | |||||
|---|---|---|---|---|---|
| Balance atbeginningof period | Charged to costsand expenses | Charged to otheraccounts | Deductions | Balance at endof period | |
| Allowance for doubtful accounts including credit losses: | |||||
| Year ended December 31, 2025 | $146 | $10 | $(9) | $(13) | 134 |
| Year ended December 31, 2024 | $164 | $35 | $(8) | $(46) | 146 |
| Year ended December 31, 2023 | $162 | $10 | $(6) | $(2) | 164 |
| Allowance in respect of carryforward tax losses and deductions that may not be utilized: | |||||
| Year ended December 31, 2025 | $2,017 | $1,036 | $— | $(710) | $2,342 |
| Year ended December 31, 2024 | $3,009 | $100 | $— | $(1,093) | $2,017 |
| Year ended December 31, 2023 | $3,072 | $161 | $— | $(224) | $3,009 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.